Blog

Imagine a future where cancer treatment isn't a grueling, months-long process involving cell extraction and reinfusion, but a simple, targeted injection that reprograms your body's own immune cells to fight disease from within. This isn't science fiction; it's the rapidly emerging reality of in vivo CAR-T engineering, a revolutionary approach poised to transform immunotherapy and bring 'off-the-shelf' treatments closer than ever before. Introduction Chimeric Antigen Receptor (CAR) T-cell therapy has already revolutionized the treatment landscape for certain blood cancers, offering a powerful new weapon against previously intractable diseases. However, the traditional 'ex vivo' manufacturing …